IMM-27M
- Generic Name
- IMM-27M
Alto's ALTO-300 Shows Promise in Phase 2b Trial for Treatment-Resistant Depression
• Alto Neuroscience's ALTO-300, a novel biomarker-based antidepressant, advances in Phase 2b trial for Major Depressive Disorder with topline results expected by mid-2026.
• The company's robust pipeline includes ALTO-203 for anhedonia, ALTO-101 for cognitive impairment in schizophrenia, and ALTO-100 for bipolar depression, with multiple data readouts expected in 2025-2026.
• Previous open-label Phase 2a data demonstrated ALTO-300's superior efficacy in biomarker-positive patients, showing a 17-point MADRS improvement compared to 12.3 points in biomarker-negative patients.
ImmuneOnco's IMM27M Shows Promise in Phase I Breast Cancer Trial, Advancing to Phase II
• ImmuneOnco's IMM27M demonstrated a 25% overall response rate and a 75% disease control rate in a Phase I study for estrogen receptor-positive advanced breast cancer.
• The Phase I trial established IMM27M's safety and tolerability, with no dose-limiting toxicities observed at the highest dose tested.
• Based on these encouraging Phase I results, ImmuneOnco has initiated a Phase II clinical trial to further evaluate IMM27M's efficacy.
• IMM27M targets estrogen receptor-positive advanced breast cancer, addressing a significant unmet need in patients with this condition.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath